|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hydroxytryptamine transporter gene-linked polymorphic region(5HTTLPR)is associated with delusions in Alzheimer’s disease显示文摘Background:Serotoninergic pathways underlying delusion symptoms in Alzheimer’s disease(AD)have not been fully clarified.5-Hydroxytryptamine transporter gene-linked polymorphic region(5-HTTLPR)is a variable number tandem repeats in the promoter region of serotonin transporter encoding-gene affecting transcription.Methods:We investigated the association of 5-HTTLPR with delusions in a total of 257 consecutive patients clinically diagnosed as AD according to the National Institute on Aging-Alzheimer’s Association criteria.All participants underwent a comprehensive evaluation with a standardized comprehensive geriatric assessment and Neuropsychiatric Inventory.Results:Delusion symptoms were observed in 171 patients(66.54%).In respect to AD patients without delusions,AD patients with delusions showed a low prevalence of S-plus carriers(5-HTTLPR-L/S+5-HTTLPR-S/S genotypes)[p<0.001;odds ratio(OR)=0.240,95% confidence interval(CI)=0.121–0.471].Logistic regression analysis adjusted for the apolipoprotein E polymorphism showed that in AD patients with delusions the presence of an 5-HTTLPR-S allele may reduce disease duration(p=0.005;OR=0.680,95% CI=0.522–0.886)and increase aberrant motor activity(p=0.013;OR=2.257,95% CI=1.195–4.260).The present findings suggested that 5-HTTLPR might be associated with delusions in AD.S-plus carriers might be associated with protective effect against delusions in AD.Conclusions:More studies on wider samples of high selected demented patients are needed to confirm our results.However,the present findings suggested that a genetic factor related to serotonin metabolism might exert a protective role on the clinical expression of neuropsychiatric clusters in AD with important implications regarding mechanisms underlying delusions and their possible treatment across the AD and dementia spectrum. | Grazia D’Onofrio Francesco Panza Daniele Sancarlo Michele Lauriola Mariangela P.Dagostino Giulia Paroni Madia Lozupone Antonio Mangiacotti Paola Bisceglia Carolina Gravina Maria Urbano Filomena Addante Francesco Paris Leandro Cascavilla Antonio Greco Davide Seripa | 2019 | Translational Neurodegeneration2019，8，1： | 2 |
| 2 | Extended fault-location formulation for power distribution systems显示文摘 | Salim R H Resener M Filomena A D | 2009 | Power Delivery IEEE Trans on Industrial Electronics2009，24，2： | 1 |
| 3 | Hybrid fault diagnosis scheme implementation for power distribution systems automation显示文摘 | Salim R H de Oliveira K Filomena A D | 2008 | IEEE Trans on Power Delivery2008，23，4： | 1 |
| 4 | Hybrid fault diagnosis scheme implementation for power distribution systems automation显示文摘 | Filomena A D Salim R H de Oliveira K | 2008 | IEEE Trans on Power Delivery2008，23，4： | 1 |
| 5 | Coffee reduces liver damage in a rat model of steatohepatitis: The underlying mechanisms and the role of polyphenols and melanoidins显示文摘 | Paola Vitaglione Filomena Morisco Giovanna Mazzone Daniela Caterina Amoruso Maria Teresa Ribecco Antonietta Romano Vincenzo Fogliano Nicola Caporaso Giuseppe D’Argenio | 2010 | Hepatology2010，，5： | 1 |
| 6 | Hybrid fault diagnosis scheme implementation for power distribution systems automation显示文摘 | Salim R H de Oliveira K Filomena A D | 2008 | IEEE Trans on Power Delivery2008，23，4： | 1 |
| 7 | Evidence for oxidative actvation of c-myc-dependent nuclear signaling in human coronary smooth muscle cells and in early lesions of Watanabe heritable hyperlipidemic rabbits protective effects of vitamin E显示文摘 | Filomena D Tammam Y Silvia A | 2000 | Circulation2000，102，11： | 1 |
| 8 | Extended fault-location formulation for power distribution systems显示文摘 | SALIM R H RESENER M FILOMENA A D | 2009 | IEEE Trans on Power Delivery2009，24，2： | 1 |
| 9 | Extendedfault-location formulation for power distribution systems 显示文摘 | SALIM R H RESENER M FILOMENA A D | 2009 | IEEE Transactions on Power Delivery f2009，24，2： | 1 |
| 10 | Boceprevir or telaprevir in hepatitis C virus chronic infection:The Italian real life experience显示文摘AIM: To check the safety and efficacy of boceprevir/telaprevir with peginterferon/ribavirin for hepatitis C virus(HCV) genotype 1 in the real-world settings. METHODS: This study was a non-randomized, observational, prospective, multicenter. This study involved 47 centers in Italy. A database was prepared for the homogenous collection of the data, was used by all of the centers for data collection, and was updated continuously. All of the patients enrolled in this study were older than 18 years of age and were diagnosed with chronic infection due to HCV genotype 1. The HCV RNA testing was performed using COBAS-Taq Man2.0(Roche, LLQ 25 IU/m L). RESULTS: All consecutively treated patients were included. Forty-seven centers enrolled 834 patients as follows: Male 64%; median age 57(range 18-78), of whom 18.3% were over 65; mean body mass index 25.6(range 16-39); genotype 1b(79.4%); diagnosis of cirrhosis(38.2%); and fibrosis F3/4(71.2%). The following drugs were used: Telaprevir(66.2%) and PEG-IFN-alpha2a(67.6%). Patients were na?ve(24.4%), relapsers(30.5%), partial responders(14.8%) and null responders(30.3%). Overall, adverse events(AEs) occurred in 617 patients(73.9%) during the treatment. Anemia was the most frequent AE(52.9% of cases), especially in cirrhotic. The therapy was stopped for 14.6% of the patients because of adverse events or virological failure(15%). Sustained virological response was achieved in 62.7% of the cases, but was 43.8% in cirrhotic patients over 65 years of age. CONCLUSION: In everyday practice, triple therapy is safe but has moderate efficacy, especially for patients over 65 years of age, with advanced fibrosis, nonresponders to peginterferon + ribavirin. | Antonio Ascione Luigi Elio Adinolfi Pietro Amoroso Angelo Andriulli Orlando Armignacco Tiziana Ascione Sergio Babudieri Giorgio Barbarini Michele Brogna Francesco Cesario Vincenzo Citro Ernesto Claar Raffaele Cozzolongo Giuseppe D’Adamo Emilio D’Amico Pellegrino Dattolo Massimo De Luca Vincenzo De Maria Massimo De Siena Giuseppe De Vita Antonio Di Giacomo Rosanna De Marco Giorgio De Stefano Giulio De Stefano Sebastiano Di Salvo Raffaele Di Sarno Nunzia Farella Laura Felicioni Basilio Fimiani Luca Fontanella Giuseppe Foti Caterina Furlan Francesca Giancotti Giancarlo Giolitto Tiziana Gravina Barbara Guerrera Roberto Gulminetti Angelo Iacobellis Michele Imparato Angelo Iodice Vincenzo Iovinella Antonio Izzi Alfonso Liberti Pietro Leo Gennaro Lettieri Ileana Luppino Aldo Marrone Ettore Mazzoni Vincenzo Messina Roberto Monarca Vincenzo Narciso Lorenzo Nosotti Adriano Maria Pellicelli Alessandro Perrella Guido Piai Antonio Picardi Paola Pierri Grazia Pietromatera Francesco Resta Luca Rinaldi Mario Romano Angelo Rossini Maurizio Russello Grazia Russo Rodolfo Sacco Vincenzo Sangiovanni Antonio Schiano Antonio Sciambra Gaetano Scifo Filomena Simeone Annarita Sullo Pierluigi Tarquini Paolo Tundo Alfredo Vallone | 2016 | World Journal of Hepatology2016，8，22： | 1 |
| 11 | Garlic extract attenuating rat liver fibrosis by inhibiting TGF-β1显示文摘 | Giuseppe D’Argenio Giovanna Mazzone Maria T. Ribecco Vincenzo Lembo Paola Vitaglione Maria Guarino Filomena Morisco Manuela Napolitano Vincenzo Fogliano Nicola Caporaso | 2012 | Clinical Nutrition2012，，： | 1 |
| 12 | The Comprehensive Geriatric Assessment and the multidimensional approach. A new look at the older patient with gastroenterological disorders显示文摘 | Alberto Pilotto Filomena Addante Grazia D’Onofrio Daniele Sancarlo Luigi Ferrucci | 2009 | Best Practice & Research Clinical Gastroenterology2009，，6： | 1 |
| 13 | Hybrid fault diagnosis scheme implementation for power distribution systems automation显示文摘 | Salim R H de Oliveira K Filomena A D | 2008 | IEEE Transactions on Power Delivery2008，23，4： | 1 |
| 14 | Advances in bacterial ex opolysaccharides: from production to bioteehnological application 显示文摘 | FILOMENA F VITOR D A MARIA A M R | 2011 | Trends Biotechnol2011，29，8： | 1 |
| 15 | Randomized phase III clinical trial of a combined treatment with carnitine megestrol acetate for patients with cancer-related anorexia/cachexia syndrome显示文摘 | Clelia M Mariele D Filomena P | 2012 | Cancer Res2012，72，4： | 1 |
| 16 | Traffic calming along rural highways crossing small urban communities: Driving simulator experiment显示文摘 | Francesco Galante Filomena Mauriello Alfonso Montella Mariano Pernetti Massimo Aria Antonio D’Ambrosio | 2010 | Accident Analysis and Prevention2010，，6： | 1 |
| 17 | Garlic extract attenuating rat liver fibrosis by inhibiting TGF-β1显示文摘 | Giuseppe D’Argenio Giovanna Mazzone Maria T. Ribecco Vincenzo Lembo Paola Vitaglione Maria Guarino Filomena Morisco Manuela Napolitano Vincenzo Fogliano Nicola Caporaso | 2012 | Clinical Nutrition2012，，： | 1 |
| 18 | Extended fault-location formulation for power distribution systems 显示文摘 | SAIAM R H RESENER M FILOMENA A D | 2009 | IEEE Transactions on Power Delivery2009，24，2： | 1 |
| 19 | Extended fault-location formulation for power distribution systems 显示文摘 | SALIM R H RESENER M FILOMENA A D | 2009 | IEEE Transactions on Power Delivery2009，24，2： | 1 |
| 20 | Polymorphism AGT2(rs4762)is involved in the development of dermatologic events:Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib显示文摘BACKGROUND Dermatologic adverse events(DAEs)are associated with a better outcome in patients with hepatocellular carcinoma(HCC)irrespective of the therapeutic agent received.The exact mechanisms associated with the development of DAEs are unknown although several studies point to direct toxicity of tyrosine kinase inhibitors(TKIs)to the skin or an immune-mediated reaction triggered by the oncologic treatment.As is the case in other conditions,individual genetic variants may partially explain a higher risk of DAEs.AIM To evaluate the contribution of several gene variants to the risk of developing DAEs in HCC patients treated with TKIs.METHODS We first analyzed 27 single-nucleotide polymorphisms(SNPs)from 12 genes selected as potential predictors of adverse event(AE)development in HCC patients treated with sorafenib[Barcelona Clinic Liver Cancer 1(BCLC1)cohort].Three additional cohorts were analyzed for AGT1(rs699)and AGT2(rs4762)polymorphisms-initially identified as predictors of DAEs:BCLC2(n=79),Northern Italy(n=221)and Naples(n=69)cohorts,respectively.The relation between SNPs and DAEs and death were assessed by univariate and multivariate Cox regression models,and presented with hazard ratios and their 95%confidence intervals(95%CI).RESULTS The BCLC1 cohort showed that patients with arterial hypertension(AHT)(HR=1.61;P value=0.007)and/or AGT SNPs had an increased risk of DAEs.Thereafter,AGT2(rs4762)AA genotype was found to be linked to a statistically significant increased probability of DAEs(HR=5.97;P value=0.0201,AA vs GG)in the Northern Italy cohort by multivariate analysis adjusted for BCLC stage,ECOG-PS,diabetes and AHT.The value of this genetic marker was externally validated in the cohort combining the BCLC1,BCLC2 and Naples cohorts[HR=3.12(95%CI:1.2-8.14),P value=0.0199,AGT2(rs4762)AA vs AG genotype and HR=2.73(95%CI:1.18-6.32)P value=0.0188,AGT2(rs4762)AA vs GG genotype].None of the other gene variants tested were found to be associated with the risk of DAE development.CONCLUSION DAE development in HCC patients receiving TKIs could be explained by the AGT2(rs4762)gene variant.If validated in other anti-oncogenic treatments,it might be considered a good prognosis marker. | Víctor Sapena Massimo Iavarone Loreto Boix Floriana Facchetti Maria Guarino Marco Sanduzzi Zamparelli Alessandro Granito Esther Samper Mario Scartozzi Josep Corominas Giorgia Marisi Alba Díaz Andrea Casadei-Gardini Laura Gramantieri Pietro Lampertico Filomena Morisco Ferran Torres Jordi Bruix María Reig | 2022 | World Journal of Hepatology2022，14，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员